天津医药
天津醫藥
천진의약
TIANJIN MEDICAL JOURNAL
2013年
8期
756-758
,共3页
翟浩宇%张志广%姜葵%李熳
翟浩宇%張誌廣%薑葵%李熳
적호우%장지엄%강규%리만
淋巴瘤, B细胞,边缘区%螺杆菌,幽门%β防御素%胃肿瘤%胃MALT淋巴瘤
淋巴瘤, B細胞,邊緣區%螺桿菌,幽門%β防禦素%胃腫瘤%胃MALT淋巴瘤
림파류, B세포,변연구%라간균,유문%β방어소%위종류%위MALT림파류
lymphoma,B-cell,marginal zone%helicobacter pylori%beta-defensins%stomach neoplasms%gastric MALT lymphoma
目的研究人β防御素-2(HBD-2)在幽门螺杆菌(H. pylori)相关胃黏膜相关淋巴组织(MALT)淋巴瘤患者胃黏膜中的表达情况,探讨HBD-2在胃MALT淋巴瘤中的作用。方法收集40例在根除治疗前H. pylori(+)且根除治疗后H. pylori为(-)的胃MALT淋巴瘤患者的胃黏膜组织作为HP组,同时收集36例H. pylori(-)的慢性浅表性胃炎患者胃黏膜组织作为对照组,用免疫组化法检测HBD-2的表达情况。结果 HBD-2在H. pylori相关胃MALT淋巴瘤中的表达水平高于对照组(P<0.01);根除H. pylori治疗后,HP组HBD-2表达水平降低(P<0.01);且HBD-2在H. pylori相关胃MALT淋巴瘤间质细胞的表达水平高于淋巴瘤细胞(P<0.01);HBD-2在淋巴瘤细胞中无表达。结论 HBD-2可能参与了H. pylori相关胃MALT淋巴瘤的发病过程;但是否具有抗肿瘤作用尚不明确。
目的研究人β防禦素-2(HBD-2)在幽門螺桿菌(H. pylori)相關胃黏膜相關淋巴組織(MALT)淋巴瘤患者胃黏膜中的錶達情況,探討HBD-2在胃MALT淋巴瘤中的作用。方法收集40例在根除治療前H. pylori(+)且根除治療後H. pylori為(-)的胃MALT淋巴瘤患者的胃黏膜組織作為HP組,同時收集36例H. pylori(-)的慢性淺錶性胃炎患者胃黏膜組織作為對照組,用免疫組化法檢測HBD-2的錶達情況。結果 HBD-2在H. pylori相關胃MALT淋巴瘤中的錶達水平高于對照組(P<0.01);根除H. pylori治療後,HP組HBD-2錶達水平降低(P<0.01);且HBD-2在H. pylori相關胃MALT淋巴瘤間質細胞的錶達水平高于淋巴瘤細胞(P<0.01);HBD-2在淋巴瘤細胞中無錶達。結論 HBD-2可能參與瞭H. pylori相關胃MALT淋巴瘤的髮病過程;但是否具有抗腫瘤作用尚不明確。
목적연구인β방어소-2(HBD-2)재유문라간균(H. pylori)상관위점막상관림파조직(MALT)림파류환자위점막중적표체정황,탐토HBD-2재위MALT림파류중적작용。방법수집40례재근제치료전H. pylori(+)차근제치료후H. pylori위(-)적위MALT림파류환자적위점막조직작위HP조,동시수집36례H. pylori(-)적만성천표성위염환자위점막조직작위대조조,용면역조화법검측HBD-2적표체정황。결과 HBD-2재H. pylori상관위MALT림파류중적표체수평고우대조조(P<0.01);근제H. pylori치료후,HP조HBD-2표체수평강저(P<0.01);차HBD-2재H. pylori상관위MALT림파류간질세포적표체수평고우림파류세포(P<0.01);HBD-2재림파류세포중무표체。결론 HBD-2가능삼여료H. pylori상관위MALT림파류적발병과정;단시부구유항종류작용상불명학。
Objective To investigate the expression of humanβ-defensin 2 (HBD-2) in gastric mucosa of Helico-bacter pylori (H. pylori) associated gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and the role of HBD-2 in gastric MALT lymphoma. Methods Forty gastric mucosa specimens from patients with H. pylori associated gastric MALT lymphoma were collected. And 36 gastric mucosa specimens from chronic superficial gastritis without H. pylori infection were included as control group. The expression of HBD-2 was detected by immunohistochemistry staining. Results The ex-pression of HBD-2 was significantly higher in H. pylori associated gastric MALT lymphoma than that of control group. (P<0.01). The expression of HBD-2 was significantly decreased after the eradication of H. pylori (P<0.01). The expression of HBD-2 was significantly higher in H. pylori associated gastric MALT lymphoma than that of lymphoma cells (P<0.01). There was no expression of HBD-2 in lymphoma cells. Conclusion HBD-2 is possibly involved in the pathogenesis of H. pylori associated gastric MALT lymphoma. But whether it has anti-tumor effect is not clear.